Concepedia

Deolinda Pereira

DP

Statistics

Publications

51

Citations

3.6K

H-Index

28

Active since

2002

Affiliations

Instituto Português de Oncologia Francisco Gentil(Current)

Universidade do Porto

IPO Porto

Fernando Pessoa University

Portuguese League Against Epilepsy

Deolinda Pereira is an author at Instituto Português de Oncologia Francisco Gentil specializing in medicine, oncology, and molecular oncology.

ORCID

Publications per year

2002–2024

51

Publications

51

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

Éric Pujade-Lauraine, Felix Hilpert, B. Weber et al. · Journal of Clinical Oncology · 2014 · 1.6K citations · Full text

, , +17

AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).

Éric Pujade-Lauraine, Felix Hilpert, B. Weber et al. · Journal of Clinical Oncology · 2012 · 136 citations

, , +17

Importance of TP53 codon 72 and intron 3 duplication 16bppolymorphisms in prediction of susceptibility on breast cancer

Sandra Costa, Daniela Pinto, Deolinda Pereira et al. · BMC Cancer · 2008 · 123 citations · Full text

, , +17

AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).

Éric Pujade-Lauraine, Felix Hilpert, B. Weber et al. · Journal of Clinical Oncology · 2012 · 117 citations

, , +17

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients

Ian E. Smith, Jean‐Yves Pierga, Laura Biganzoli et al. · Annals of Oncology · 2010 · 104 citations · Full text

, , +14

1–5 of 51